🔎 Trials Near Me

Home › Bladder Cancer › Pennsylvania

Bladder Cancer clinical trials in Pennsylvania

27 studies for Bladder Cancer are looking for participants at sites in Pennsylvania.

Cities in Pennsylvania

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

  • Geisinger Medical Center, Danville
  • Geisinger Cancer Center Dickson City, Dickson City
  • Geisinger Medical Oncology-Lewisburg, Lewisburg
  • and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07000084

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

  • Christiana Care Health System-Concord Health Center, Chadds Ford
  • Geisinger Medical Center, Danville
  • Geisinger Cancer Center Dickson City, Dickson City
  • and 17 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06770582

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

  • MidLantic Urology ( Site 0102), Bala-Cynwyd
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06833073

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
  • Asplundh Cancer Pavilion, Willow Grove
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07061964

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Pocono Medical Center, East Stroudsburg
  • and 8 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413

DESTINY-PANTUMOUR04

  • Research Site, Philadelphia
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
  • AHN Allegheny General Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380

Prehabilitation in High-risk Oncologic Surgery

  • Fox Chase Cancer Center - Philadelphia, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07638410

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07217171

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of Pennsylvania, Philadelphia
  • WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  • Midlantic Urology (Solaris), Bala-Cynwyd
  • Penn State University Milton S. Hershey Medical Center, Hershey
  • Keystone Urology Specialists, Lancaster
  • and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06567743

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

  • University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05951179

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

  • Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
  • University of Pennsylvania, Philadelphia
  • Thomas Jefferson University, Philadelphia
  • and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  • Christiana Care Health System-Concord Health Center, Chadds Ford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07097142

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Thomas Jefferson University, Philadelphia
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

  • Penn State Medical Center, Urology Research, Hershey
Recruiting
Ages 18 to 88 · All sexes · Updated Jul 2, 2026 · NCT06394869

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

  • University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT06586255

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

  • Abramson Cancer Center, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT07048496

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

  • Allegheny Health Network, Pittsburgh
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT04075305

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

  • Thomas Jefferson University Hospital, Philadelphia
  • Jefferson Einstein Philadelphia Hospital, Philadelphia
Recruiting
Ages 18 to 85 · All sexes · Updated Feb 17, 2026 · NCT07234968

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

  • UPMC Hillman Cancer Center - Dept of Urology, Pittsburgh
RecruitingEarly phase 1
Ages 18 to 90 · All sexes · Updated Dec 17, 2025 · NCT04369560

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.